1. Show article details.

    Blow to Roche's cancer immunotherapy prospects as 2nd trial fails

    Reuters – 2:16 AM ET 05/11/2022

    * Drug candidate tiragolumab previously flunked trial in March. * Anti-TIGIT class of drugs has attracted several rivals. * Roche says trial will continue after disappointing interim data. By Ludwig Burger. May 11 - Development of a new cancer immunotherapy pioneered by Roche was thrown in doubt on Wednesday when the drug, tiragolumab, failed to slow progression of lung cancer in a second trial.

  2. Show article details.

    Analyzing Merck & Co's Short Interest

    Benzinga – 2:04 PM ET 05/10/2022

    Merck & Co's short percent of float has risen 14.93% since its last report. Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock.

  3. Show article details.

    Merck To Present Data at 2022 ASCO Annual Meeting Highlighting Promising Pipeline Medicines and Significant Progress in Treating Earlier Stages of Certain Cancers With KEYTRUDA® (pembrolizumab)

    Business Wire – 6:45 AM ET 05/10/2022

    Data from studies of six medicines and pipeline candidates in more than 25 cancers to be presented Merck (MRK), known as MSD outside the United States and Canada, today announced that data for six approved medicines and pipeline candidates in more than 25 types of cancer will be presented at the 2022 American Society of Clinical Oncology Annual Meeting in Chicago from June 3-7.

  4. Show article details.

    CNBC's Final Trades: Honeywell International, Merck And More

    Benzinga – 7:37 AM ET 05/05/2022

    On CNBC's "Halftime Report Final Trades," Stephen Weiss of Short Hills Capital Partners chose Invesco QQQ Trust Series 1. "The market will rally off the Fed," Weiss said. For those intending to ride the rally, he recommended to "use a tight stop on it, so you don't get run over." Liz Young of BNY Mellon Investment Management chose the Vanguard Short-Term Treasury Index Fund ETF.

  5. Show article details.

    Organon Reports Results for the First Quarter Ended March 31, 2022

    Business Wire – 7:30 AM ET 05/05/2022

    JERSEY CITY, N.J.---- Organon, today announced its results for the first quarter ended March 31, 2022. "The first quarter marked a solid start to the year. Total net revenue was $1,567 million for the first quarter of 2022, an increase of 4% as-reported and an increase of 8% excluding the impacts of foreign currency, compared with the first quarter of 2021.

  6. Show article details.

    4 Stocks Moved By Traders on 'Fast Money: Halftime Report'

    Benzinga – 1:46 PM ET 05/04/2022

    CNBC's "Fast Money: Halftime Report" delivers market-moving news to investors. The commentary delivered by hosts of the show often moves the stocks mentioned. Broadcom Inc 12:30 P.M. - Stephanie Link mentioned she sold Broadcom, shares slid 0.07% lower in the following 30 minutes.

  7. Show article details.

    Merck to Participate in Bank of America Securities 2022 Healthcare Conference

    Business Wire – 6:45 AM ET 05/04/2022

    Merck (MRK), known as MSD outside the United States and Canada, today announced that Executive Vice President and Chief Financial Officer Caroline Litchfield will participate in a fireside chat at the live Bank of America Securities 2022 Healthcare Conference. The conversation will take place Wednesday, May 11, at 11:40 a.m. ET.

  8. Show article details.

    BRIEF-Imugene Announces Termination Of Supply Agreement With MSD

    Reuters – 6:19 AM ET 05/02/2022

    Imugene Ltd (IUGNF): * ANNOUNCED TERMINATION OF ITS SUPPLY AGREEMENT WITH MSD Source text for Eikon: Further company coverage:

  9. Show article details.

    The Nasdaq, S&P 500 And Dow Took A Big Dive In April

    Benzinga – 4:15 PM ET 04/29/2022

    Markets finished off the month of April down big amid a mixed first-quarter earnings season. For the month, the Nasdaq fell 15%, the S&P 500 fell 10.2% and the Dow fell 6.4%. On Thursday, the Commerce Department reported first-quarter U.S. GDP fell 1.4%, well short of economists' expectations of 1% growth.

  10. Show article details.

    What 7 Analyst Ratings Have To Say About Merck & Co

    Benzinga – 9:23 AM ET 04/29/2022

    Over the past 3 months, 7 analysts have published their opinion on Merck & Co stock. These 7 analysts have an average price target of $97.43 versus the current price of Merck & Co at $88.61, implying upside. Below is a summary of how these 7 analysts rated Merck & Co over the past 3 months.

  11. Show article details.

    The Daily Biotech Pulse: FDA Approves Bristol Myers' Oral Heart Disease Drug, European Approval For Merck's Keytruda, Genocea Restructures, Zymeworks' Takeover Bid

    Benzinga – 9:00 AM ET 04/29/2022

    Here's a roundup of top developments in the biotech space over the last 24 hours. The FDA has approved Bristol Myers Squibb & Co's  Camzyos for obstructive hypertrophic cardiomyopathy to improve functional capacity and symptoms. Camzyos is the first and only FDA-approved allosteric and reversible inhibitor selective for cardiac myosin that targets the underlying pathophysiology of obstructive HCM.

  12. Show article details.

    BRIEF-Biocytogen Enters into Antibody Agreement with Merck

    Reuters – 8:08 AM ET 04/29/2022

    Merck & Co Inc (MRK): * BIOCYTOGEN PHARMACEUTICALS CO., LTD. - ENTERED INTO EVALUATION AND OPTION AGREEMENT WITH MERCK Source text for Eikon: Further company coverage:

  13. Show article details.

    BRIEF-European Commission Approves Merck's Keytruda (Pembrolizumab)

    Reuters – 7:00 AM ET 04/29/2022

    Merck & Co Inc (MRK): * EUROPEAN COMMISSION APPROVES MERCK'S KEYTRUDA® FOR PATIENTS WITH MICROSATELLITE INSTABILITY-HIGH OR DEFICIENT MISMATCH REPAIR TUMORS IN FIVE DIFFERENT TYPES OF CANCER. * MERCK (MRK) - APPROVAL ALLOWS MARKETING OF KEYTRUDA MONOTHERAPY IN ALL EUROPEAN UNION MEMBER STATES PLUS ICELAND, LICHTENSTEIN, NORWAY AND NORTHERN IRELAND Source text for Eikon: Further company coverage:

  14. Show article details.

    European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) for Patients With Microsatellite Instability-High (MSI-H) or Deficient Mismatch Repair (dMMR) Tumors in Five Different Types of Cancer

    Business Wire – 6:45 AM ET 04/29/2022

    KEYTRUDA is the First Immunotherapy to be Approved for Patients with MSI-H/dMMR Biomarkers in Five Different Types of Cancer in Europe Merck (MRK), known as MSD outside the United States and Canada, today announced that the European Commission has approved KEYTRUDA, Merck’s anti-PD-1 therapy, as monotherapy for the treatment of microsatellite instability-high or deficient mismatch repair tumors in ...

  15. Show article details.

    European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy, With or Without Bevacizumab, for Patients With Persistent, Recurrent or Metastatic Cervical Cancer Whose Tumors Express PD-L1 (CPS ≥1)

    Business Wire – 6:30 AM ET 04/29/2022

    First Immunotherapy-Based Regimen Approved in Europe for These Patients With Persistent, Recurrent or Metastatic Cervical Cancer Approval Based on Overall Survival Benefit Demonstrated in Phase 3 KEYNOTE-826 Trial Merck (MRK), known as MSD outside the United States and Canada, today announced that the European Commission has approved KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with chemothe...

  16. Show article details.

    Markets Surge Despite Drop In US GDP

    Benzinga – 4:10 PM ET 04/28/2022

    U.S. indices traded higher Thursday despite a drop in U.S. GDP. U.S. GDP unexpectedly declined 1.4% in the first quarter, falling well short of consensus economist estimates of 1% growth... Here are the day's winners and losers from the Dow Jones, according to data from Benzinga Pro. Salesforce Inc, Merck & Co., Inc. and Nike Inc were among the top gainers for the DIA.

  17. Show article details.

    Mental health issues in kids rose during pandemic; awareness and use of COVID treatments is low

    Reuters – 2:59 PM ET 04/28/2022

    - The following is a summary of some recent studies on COVID-19. Pandemic linked with mental health issues in kids. The COVID-19 pandemic has profoundly impacted the mental health of children and adolescents, researchers say, based on their analysis of findings from 17 earlier studies.

  18. Show article details.

    COVID SCIENCE-Mental health issues in kids rose during pandemic; awareness and use of COVID treatments is low

    Reuters – 2:54 PM ET 04/28/2022

    The following is a summary of some recent studies on COVID-19. Pandemic linked with mental health issues in kids. The COVID-19 pandemic has profoundly impacted the mental health of children and adolescents, researchers say, based on their analysis of findings from 17 earlier studies.

  19. Show article details.

    Surprise Negative GDP Report Could Hurt Premarket Rally

    Benzinga – 12:16 PM ET 04/28/2022

    This post contains sponsored advertising content. The bulls approached another run as the major indexes try to stay above key support levels.

  20. Show article details.

    Are These Global Companies On The Right Side Of History?

    Benzinga – 12:08 PM ET 04/28/2022

    Despite a global boycott of Russia and an international condemnation of the Kremlin's actions against Ukraine, some multinationals have dismissed demands to exit or scale down their presence in Russia for various reasons and choosing to continue business-as-usual. The conflict between Russia and Ukraine has dragged on for two months now since Russia started invading Ukraine on Feb. 24.

Page:

Today's and Upcoming Events

  • Jul
    28

    MRK to announce Q2 earnings (Confirmed)

Past Events (last 90 days)

  • Jun
    14

    MRK ex-Dividend for $0.69 on 06/14/2022

    • Announce Date: 05/24/2022
    • Record Date: 06/15/2022
    • Pay Date: 07/08/2022
  • Apr
    28

    MRK announced Q1 earnings.

Data provided by Thomson Reuters © 2022

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.